

Receipt date: 12/08/2005

10/560062 18

IAP9 Rec'd PCT/PTO 08 DEC 2005

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PN0323SERIAL NO.
To be assignedINFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Alan Cuthbertson, et.al.

FILING DATE

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2002/102217	08-2202	Hellebust, et.al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	10808501	08-1999	DE				
	01/77145	10-2001	WO				
	02/26776	04-2002	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Katada, et.al., "A Novel Motif for Platelet Fibrinogen Receptor Recognition" The Journal of Biological Chemistry, vol. 272, no. 12, 21 March 1997, pages 7720-7726
	Reicke, B., et.al. "Topical Application of Integrin Antagonists Inhibits Proliferative Retinopathy" Hormone and Metabolic Research, vol. 33, no. 5, May 2001, pages 307-311
	De Groot F.M.H., et.al., "Design, Synthesis, and Biological Evaluation of a Dual Tumor-Specific Motive Containing Integrin-Targeted Plasmin-Cleavable Doxorubicin Prodrug" Molecular Cancer Therapeutics, American Assoc. of Cancer Research, US, vol. 1, Sept. 2002, pages 901-911
	Int'l Search Report PCT/NO2004/000208 dated December 2004
	Int'l Preliminary Exam report PCT/NO2004/000208 dated Sept. 2005

/D. Jones/

EXAMINER

DATE CONSIDERED

12/5/08

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJ/